30 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
. Rademikibart was generally well tolerated with no unexpected safety signals.
oAnnounced positive long-term data from the China pivotal trial in patients … positive long-term data from the maintenance period through Week 48 of CN002 phase 2 icanbelimod trial in patients with moderate-to-severe ulcerative
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
Exhibit 99.2
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
and Chief Executive Officer of Connect Biopharma. “We also reported positive long-term data from the Phase 2 maintenance period in ulcerative colitis with our … expected by end of 2023.”
First Half 2023 and Recent Highlights
Reported in June 2023 positive long-term data from the maintenance period through Week 48
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
through other comprehensive income ("FVOCI") are reflected as Level 1 and 2 instruments, as short-term and long-term investments. The following table … presents the changes in Level 1 and 2 instruments of short-term and long-term investments for the six months ended June 30, 2022 and 2023.
Six Months
6-K
EX-99.1
tlqw 60wgxj
5 Jun 23
Current report (foreign)
4:28pm
6-K
EX-99.1
rxeq 556skipv172t3
1 Jun 23
Current report (foreign)
4:24pm
6-K
gpjce
1 Jun 23
Current report (foreign)
4:24pm
6-K
EX-99.1
ezj284ouf8ummu
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
6-K
hm4hi65r1u ma94
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
EX-99.1
34mmj9ghd3p5r
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-3/A
q23ngm 9ri
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
F-3/A
l2fhu3pc
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
EX-99.2
fq5o dfuh
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
tzl d62ctcu85nt
15 Apr 22
Shelf registration (foreign)
5:27pm
F-3
EX-1.2
r57a 09a1h1fzobvfac
15 Apr 22
Shelf registration (foreign)
5:27pm
20-F
3c0a47fy73unonb
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.10
gxcu111v
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
x45xssh
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am